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The European Council Directive 97/43/EURATOM introduce specific 
requirements aimed at the reduction of the probability and the 
magnitude of accidents in radiotherapy. Within a European 
Commission (EC) project, the implementation of these requirements 
in radiotherapy in Europe is reviewed through detailed web-based 
questionnaires, focusing on the national systems of risk management 
in external beam radiotherapy and the national systems for 
classification, recording and reporting of adverse events or near 
misses concerning patient safety in external beam radiotherapy. The 
results, together with a review of available international systems 
related to risk management, are used to prepare European guidelines 
on a risk analysis of accidental and unintended exposures in external 
beam radiotherapy.  
The results of the questionnaires reveals that more than half of the 
countries already implemented the legal basis for risk analysis and 
event’s classification, recording and reporting. However, the lack of 
this basis in many countries and the lack of practical implementation 
in most of the countries highlight the need for further European 
guidelines.   
The guidelines under preparation will review the available risk 
assessment methodologies, both general methodologies like Event 
Tree, Fault Tree and Process analysis including critical point, and 
methodologies dedicated to radiotherapy such as Failure Mode and 
Effects Analysis (FMEA) and Risk Matrix. The risk assessment 
methodologies vary as for their purpose and capabilities in different 
steps of the risk management: hazard and failure identification, 
events’ consequence, likelihood and severity evaluation, actions 
decision process and feedback analysis. The guidelines will discuss the 
value of the various methodologies and give advice and examples on 
their application in radiotherapy, aiming to establish a minimum 
approach dedicated to radiotherapy.  
Further, basic terminology for classification and reporting of adverse 
events and near misses is proposed. Common terminology facilitates 
the analysis and comparison of reported data from different sources 
and is a key to compare the risk of radiotherapy with other health 
care areas. Existing general healthcare taxonomies with specific codes 
for radiotherapy should be used as much as possible in order to 
integrate radiotherapy reporting in existing general healthcare 
reporting systems with an important save of resources.  The event 
reporting systems should preferably be called event learning systems, 
to emphasize that reporting is only one step in a process aimed at 
learning from events.  Departmental reporting/learning systems 
should be part of the safety culture and ideally, a module in 
radiotherapy information systems.  Monitoring is fundamental to 
demonstrate the implementation of remedial actions, to close the 
cycle of learning and improving safety after an event takes place.  
The risk management envisaged in the guidelines will significantly 
contribute to the improvement of patient safety in radiotherapy.  
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Purpose/Objective: Prostate cancer is predominantly a multifocal 
disease, which consists of an index lesion and one or more satellites. 
The success of focal radiation treatment relies primarily on how well 
prostate tumors can be delineated by using MR imaging. The 
sensitivity and specificity for tumor detection on multi-parametric MRI 
is highly reduced for tumors smaller than 5 mm in diameter.  
Focal therapy for prostate cancer can be delivered in different ways. 
Focal-only therapy will treat only the visible tumor and not the whole 
prostate. Focal boost therapy (e.g. FLAME study) will treat the whole 
prostate and boost visible tumor. The aim of this study was to analyze 
distances and volumes of satellites relative to the index lesion in 
order to investigate the potential of a CTV margin for use in focal 
therapy. 
Materials and Methods: A total of 61 patients who underwent a 
radical prostatectomy were included in this study. On the H&E stained 
slides retrieved from these specimens, the uro-pathologist contoured 
the index lesion and satellites. Then the slides were digitized and 
stacked with a 4 mm distance. The slide-stacks were imported in our 
in-house developed delineation program (WorldMatch) for further 
analysis. The distance between the borders of the delineated tumors 
was measured and volumes of all delineated tumors were calculated.  
Results: Of the 61 patients, 51 (84%) had multifocal disease. The 
median number of satellites in all patients was 3. In 50% of the 
patients, the distance of the index lesion to the satellites was 1.0 cm 
or more, with a maximum of 4.4 cm. 
32% of the satellites were smaller than 5 mm in diameter. Of the total 
tumor volume 14% was located in the satellites. However, the 
contribution of satellites smaller than 5 mm to the total tumor volume 
only amounted to an average of 0.9%. 
If all tumors larger than 5 mm were assumed to be GTV, 54% of the 
patients did not have any tumor volume outside of the GTV. 
  
Conclusions: A CTV margin around the index lesion which contains all 
satellites will cover in the majority of patients nearly the entire 
prostate. The limited contribution of satellites smaller than 5 mm to 
the overall tumor load however raises the question as to their clinical 
relevance. If the small satellites are of no/little clinical relevance and 
the GTV for focal therapy includes all tumors ≥ 5 mm in diameter, 
than focal-only therapy to the GTV may be safe. If however small 
satellites are clinically relevant, treatment of the entire prostate is 
necessary with possibly a focal boost to the GTV. 
In both cases, careful screening to identify larger satellites is 
warranted. 
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Purpose/Objective: To compare the 3-dimensional intra-fraction 
variations of prostate position within the pelvis with whole-pelvic 
fixed-field intensity-modulated radiation therapy (IMRT) vs. intensity-
modulated arc therapy (IMAT) in high-risk prostate cancer (PCa). 
Materials and Methods: Fifteen PCa patients underwent whole pelvic 
radiotherapy using either dynamic IMRT with a sliding window 
technique (n= 8) or IMAT (n= 7). All the patients had a kV cone-beam 
computed tomography (CBCT) before and immediately after each 
fraction of IMRT or IMAT. 
Intra-fraction motions of the prostate were determined using a 2-step 
procedure performed on each pre- and post-treatment imaging: 1) 
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planning CT and CBCT were matched on bony structures after 
automatic semi-rigid fusion alongside the 3 axis : xbone, ybone, zbone, 2) 
planning CT and CBCT were matched on the prostate with respect to 
intra-prostatic markers: xsoft, ysoft, zsoft. The position of the prostate 
within the pelvis for each pre- and post-treatment study points was 
defined as xpros= (xbone – xsoft), ypros= (ybone – ysoft) and zpros= (zbone – zsoft).  
Rectum and bladder were outlined on each CBCT with the aim to 
assess changes in rectal or vesical repletion during each fraction. 
Organ distension was assessed by measuring the average rectal cross-
sectional area (rCSA; defined as the rectal volume divided by length), 
and the area of the bladder when evaluated 2.5cm above the prostate 
base (A-blad) on pre- and post-treatment CBCT. 
Results: Two hundred and ninety four CBCT were reviewed for this 
analysis. The average fraction duration was shorter with IMAT than 
with IMRT (4'49'', vs. 11'00'', p< 0.001). During fractions of IMRT the 
prostate showed statistically significant shifts in the longitudinal (p= 
0,049) and lateral (p=0,013) axis while it was not statistically 
significant during fractions of IMAT. Intra-fraction rCSA increased 
neither during IMAT nor IMRT whereas A-blad increased only during 
fractions of IMRT but with no correlation with prostate displacements. 
Conclusions: The prostate moves within the pelvis during an IMRT 
course which could lead to a greater daily geographic miss when 
compared to the IMAT technique.  
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Purpose/Objective: To present an innovative approach based on the 
methods of Artificial Intelligence (AI) to better predict N status in 
prostate cancer patients (pts), integrating some important clinical and 
therapeutic parameters (Gleason Score/sum, age, initial PSA, 
neoadjuvant or neoadjuvant/ concomitant hormonal therapy vs no 
hormonal therapy), known before radiotherapy (RT).  
Materials and Methods: A total of 1808 pts from a National Italian 
multicentric database was analyzed. Following the D’Amico criteria, 
we found 317 'low risk', 577 'intermediate risk' and 914'high risk' pts. 
with a known N status at diagnosis. N+pts were defined as those with 
a positive contrast enhanced pelvic MRI and/or CT scan; those showing 
a nodal only relapse after RT were also classified as N+ (as none of 
them received pelvic RT). Finally, 6/317 (1.9%), 10/577 (1.7%), 
39/914 (4.2%) such 'N+' pts were found. Using the Roach formula 
(2/3*PSA + ([Gleason-6] x 10) with a cut-off of>15%, >10% and >5%, the 
individual risk of nodal involvement was calculated. Finally, 3 AI 
classifications method, based on decision trees (the J48 method, the 
Forrest Tree method and the Random Tree method) combined with 3 
techniques of manipulation of imbalanced samples (oversampling, 
undersampling and combined under/ oversampling) were used to 
predict the N status. The accuracy of the Roach formula was 
calculated. 
Results: Table 1 resumes the performances of the Roach formula and 
of the 3 AI methods. All the proposed AI methods taking in account 
more clinical and therapeutic features perform better than the Roach 
formula. Looking at the whole population, the classic approach 
showed an accuracy (i.e. true positives + true negatives/whole 
population) rate ranging, depending on the cut-off, between 34.6% 
and 56.5%. In the same population, the 3 AI methods showed an 
accuracy rates ranging between 76.3% and 98.2%.  
For the low, intermediate and high risk patients, accuracy of the AI 
ranged between 16.7% - 99.4%, 65%-99.5% and 75.6%-98.7%. These 
methods always performed better than the Roach formula. 
The Random Forest method, combined with the Oversampling 
technique is the best method, with specificity, sensibility, and 
accuracy rates of 100%, 96.9% and 98.2%, respectively. 
Conclusions: Roach formula's is suboptimal in predicting the nodal 
status of prostate cancer patients. Non-linear relationships with more 
than two variables probably exist. New approaches taking into 
account more variables could possibly better predict the nodal status 
of the patients. 
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Purpose/Objective: In April 2010 the prospective observational study 
started with the aim of developing predictive models of genito-urinary 
(GU) toxicity and erectile dysfunction for prostate cancer patients 
(pts) treated with high dose radiotherapy (RT) delivered with 
conventional (1.8-2Gy/fr, CONV) or moderately hypo-(2.5-2.7Gy/fr 
HYPO) fractionation. In this ad-interim analysis the correlation 
between dosimetry/clinical factors and the modifications between 
pre-RT(IPSSbasal) and final (IPSSend) IPSS values were investigated. 
Materials and Methods: For all pts several clinical factors were 
collected as: T stage, hormonal therapy, smoking, use of drugs, 
presence of concomitant pathologies, previous surgery, age. Bladder 
parameters were also recovered: volume, D1%, mean dose, DVH and 
Dose Surface Histogram (DSH) in absolute and in relative value, 
referred to both the whole treatment and to the weekly delivered 
treatment (DVHw/DSHw, expected to be more predictive of acute 
symptoms). DSH were calculated using a dedicated software (Vodca, 
MSS Inc.). IPSSend≥15 was considered as end-point. Logistic uni- and 
backward multi-variate (MVA) analyses were performed. Sub-analyses 
were repeated in two selected subgroups: (1) pts with IPSSbasal<15 
(2) pts in the HYPOarm. 
Results: At the time of analysis (November 2012), 212 pts were 
available; full 3D dose-volume data were available for 177/212 (73 
CONV and 104 HYPO). IPSSend≥15 were 56/212 (26%). The dosimetry 
factors more predictive were assessed by looking to the most 
significant differences between DSH/DVH (DVHw/DSHw) of pts with 
IPSSend≥ or <15. Best predictors were the absolute bladder surface 
≥8.5Gy/week and ≥12.5 Gy/week; the correlation was also significant, 
although lower, for absolute DVHw and % DSHw/DVHw. In Fig1 the 
mean DSHw for pts with IPSSend ≥ and <15 are shown (HYPO group). 
The correlation was stronger for the HYPO group. Total DVH/DSH were 
not correlated with IPSSend≥15. At MVA (p<0.0001), the main 
independent predictors of IPSSend≥15 were: baseline IPSS (OR:1.19, 
p<0.001), S12.5w(abs) (OR:1.04, p=0.005); S8.5w(abs) (OR:1.01, 
p=0.13); use of anti-hypertensive (OR:2.08, p=0.058). The predictive 
value of the model was relatively high (AUC=78.2%, CI:71-84%).The 
independent role of S8.5w and S12.5w was confirmed when excluding 
pts with baseline IPSS≥15 (AUC=76.6%) and in the HYPO sub-group 
(AUC=76.2%).  
Fig.1 The average of DSHw for pts with IPSSend ≥ and <15. 
 
  
Conclusions: Absolute weekly DSH/DVH predicts the risk of 
IPSSend≥15 together with basal IPSS and the use of anti-hypertensive. 
The correlation was confirmed if excluding pts with large basal IPSS 
and in the HYPO subgroup. To our knowledge, this result represents 
the first evidence of a dose-volume/surface effect for acute GU 
symptoms prospectively measured in an observational study. The 
inclusion of HYPO pts likely enhanced the effect, due to the 
